Greenwich LifeSciences, Inc. — Investor Relations & Filings

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies to prevent cancer recurrence. Its lead product candidate is GLSI-100, an immunotherapy vaccine designed to prevent the recurrence of breast cancer in HER2-positive patients who have completed prior treatments. GLSI-100 combines GP2, a peptide derived from the HER2/neu protein, with the immune adjuvant GM-CSF to stimulate an immune response. A completed Phase IIb clinical trial showed a significant reduction in the five-year recurrence rate with a well-tolerated safety profile. The company is currently advancing GLSI-100 in a global, Fast Track designated Phase III clinical trial, Flamingo-01, to further evaluate its safety and efficacy.